Tagrisso (Osimertinib)

Osimertinib is a medicine used to treat a type of lung cancer that has a change in a gene called EGFR. It works by blocking a signal that tells these cancer cells to grow. It's taken as a pill by mouth.

Brand names:Tagrisso
Medication

What people taking Tagrisso (Osimertinib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Tagrisso (Osimertinib) for Non-Small Cell Lung Cancer?

NameHow it went

About Tagrisso (Osimertinib)

What It's For

Osimertinib, sold as Tagrisso, is a targeted cancer medicine for non-small cell lung cancer (NSCLC), the most common type of lung cancer. It is used only when testing of the tumor, or sometimes of a blood sample, shows a specific change in a gene called EGFR (epidermal growth factor receptor). The two most common of these changes are known as exon 19 deletions and the L858R mutation. People whose lung cancer does not carry one of these EGFR changes are not expected to benefit, which is why the test result comes before the prescription. In adults with these EGFR changes, Tagrisso is approved at several stages of the disease. After surgery to remove an early-stage tumor, it is taken to lower the chance of the cancer coming back. For cancer that cannot be removed by surgery and has been treated with chemotherapy and radiation together (stage III), it is taken afterward to keep the cancer from progressing. For cancer that has spread (metastatic), it is a standard first treatment, either alone or combined with the chemotherapy drugs pemetrexed and cisplatin or carboplatin. It is also used when cancer has grown despite an older EGFR-targeting pill and has developed a resistance change called T790M.

How It Works

EGFR is a protein on the surface of cells that acts like a switch for growth signals. In some lung cancers, a change in the EGFR gene leaves that switch stuck in the on position, and the cancer cells come to depend on its constant signal to grow and survive. Osimertinib is a type of drug called a tyrosine kinase inhibitor. It binds tightly and permanently to the mutated EGFR protein and shuts off its signal, so the cancer cells lose the message driving their growth. It acts much more strongly on the mutated forms of EGFR than on the normal form found in healthy cells. It also blocks T790M, a change that commonly lets cancer escape older EGFR-targeting pills. Osimertinib controls the cancer rather than curing advanced disease. Over time, many cancers develop new changes that let them grow again, which is why scans continue throughout treatment.

Dosage & Administration

Tagrisso is a tablet taken by mouth once a day, with or without food, at about the same time each day. The usual dose is the same for every approved use, and the care team may lower it or pause it to manage side effects. After surgery it is generally taken for up to three years; in other settings it is usually continued for as long as it keeps the cancer under control and side effects are manageable. For people who have trouble swallowing tablets, the tablet can be stirred into a small amount of plain, non-carbonated water (it breaks into small pieces rather than fully dissolving) and drunk right away, then the glass rinsed with more water and drunk to get the full dose. It should not be crushed or heated. The same method allows it to be given through a feeding tube. If a dose is missed, skip it and take the next dose at the usual time rather than doubling up. Before starting, the care team checks blood counts and, for people with heart risk factors or those also receiving chemotherapy, an ultrasound of heart function.

Side Effects

The most common side effects are diarrhea, rash, dry skin, nail changes, mouth sores, muscle or joint aches, and tiredness. Blood tests often show lower white blood cell, red blood cell or platelet counts, which usually cause no symptoms but are watched with regular blood work. Many of these effects can be managed, sometimes with a short pause or a lower dose, so it helps to report them early rather than push through. A small number of people develop serious lung inflammation (pneumonitis or interstitial lung disease), which can be fatal. It is considerably more frequent in people who recently had chemotherapy and radiation for stage III disease. New or worsening cough, shortness of breath or fever with breathing symptoms should be reported to the care team right away. Osimertinib can also affect the heart, both its electrical rhythm and its pumping strength. Dizziness, lightheadedness or fainting, or signs of heart failure such as new swelling of the legs or worsening breathlessness, should be reported promptly. Rarer serious reactions also need a prompt call: eye pain, redness, light sensitivity or blurred vision; severe blistering or peeling of the skin; persistent fever, unusual bruising or bleeding, which can point to a rare drop in all blood cells; and unexplained muscle pain or tenderness.

Interactions & Warnings

Some medicines speed up how quickly the liver breaks down osimertinib and can make it less effective. The antibiotic rifampin is one example: it cut osimertinib levels by about three quarters in a study. These strong inducers are best avoided; if one cannot be, the prescriber may raise the osimertinib dose. Because osimertinib can lengthen the heart's electrical cycle, the care team also reviews other medicines with the same effect, and may check heart tracings (ECGs) and blood minerals such as potassium and magnesium. Share a full list of prescriptions, over-the-counter medicines and supplements before starting and whenever something changes. Osimertinib can harm a developing baby. Women who could become pregnant should have a pregnancy test before starting and use effective birth control during treatment and for 6 weeks after the last dose. Men with partners who could become pregnant should use effective contraception for 4 months after the last dose. Breastfeeding is not recommended during treatment or for 2 weeks after the last dose.

What to Expect

Osimertinib is usually a long-term daily medicine, continued as long as it keeps the cancer under control. In the main trial of first treatment for advanced EGFR-mutated lung cancer, people taking osimertinib lived a median of about 38.6 months, compared with about 31.8 months with older EGFR pills, though individual outcomes vary widely. After surgery, osimertinib lowered the chance of the cancer returning and helped people live longer than placebo. After chemotherapy and radiation for stage III disease, the cancer was held in check for a median of about 39 months, compared with under 6 months without it. Follow-up includes regular scans to check the cancer, blood counts, and for some people repeat heart ultrasounds or ECGs. If the cancer eventually grows, a new biopsy or blood test may look for the resistance change behind it, which helps guide the next treatment.

Questions to Ask Your Doctor

  1. 1.Which EGFR mutation does my cancer have, and how does that affect what we expect from osimertinib?
  2. 2.Would adding chemotherapy to osimertinib help in my situation, and what extra side effects would that bring?
  3. 3.How often will I have scans, blood tests and heart checks, and what results would change the plan?
  4. 4.Which of my current medicines or supplements could interact with osimertinib or affect my heart rhythm?
  5. 5.If the cancer starts growing again, how will we find out why and what options would come next?

Last reviewed • Oct 2026

Educational content, not medical advice.